Qiulan Luo

Qiulan Luo


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2017 in BMC Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
QLQiulan Luo
Qiulan Luo
CZClaire Shuiqing Zhang
Claire Shuiqing Zhang
LYLihong Yang
Lihong Yang
AZAnthony Lin Zhang
Anthony Lin Zhang
XGXinfeng Guo
Xinfeng Guo
CLChuanjian Lu
Chuanjian Lu
Chinese herbal medicine formula Yu ping feng san (YPFS) is commonly used for allergic rhinitis (AR). Previous review had summarized the effectiveness and safety of YPFS, however without any subgroup analysis performed to provide detailed evidence for guiding clinical practice. YPFS was recommended for the management of AR by Chinese medicine clinical practice guideline, but the treatment duration of YPFS was also not specified. The aim of this study is to evaluate the effectiveness and safety of YPFS in treating adult AR with the most recent evidence, and attempt to specify the duration of utilisation through subgroup meta-analyses. Seven databases were searched from their inceptions to September 2017. Randomized controlled trials (RCTs) evaluating YPFS for adult AR were included. Methodological quality of studies was assessed using the Cochrane risk of bias tool. Meta-analysis and subgroup meta-analyses were conducted for evaluating the effectiveness of YPFS. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used for rating the quality of evidence. Twenty-two RCTs involving 23 comparisons were included in this review. YPFS was compared to placebo, pharmacotherapy, and used as an add-on treatment compared to pharmacotherapy. Meta-analyses were feasible for the outcomes of four individual nasal symptom scores and “effective rate”. Four individual nasal symptom scores decreased after YPFS’ combination treatment: itchy nose (MD-0.46, 95% CI[−0.50, −0.42]), sneezing (MD-0.41, 95% CI[−0.47, −0.35]), blocked nose (MD-0.46, 95% CI[−0.54, −0.39]) and runny nose (MD-0.42, 95% CI[−0.58, −0.26]). Based on “effective rate”, meta-analysis showed that YPFS did not achieve better effect than pharmacotherapy (RR1.07, 95%CI [0.94, 1.22), but its combination with pharmacotherapy seemed more effective than pharmacotherapy alone (RR1.27, 95%CI [1.19, 1.34]) (low quality). Subgroup analysis suggested that YPFS was not superior to the second-generation antihistamine (RR1.04, 95%CI [0.90, 1.19]) (low quality). Further, YPFS’ combination treatment seemed more beneficial when it was used for more than three weeks (RR1.15, 95%CI [1.01, 1.32]). In addition, YPFS was well-tolerated for treating adult AR. Chinese herbal medicine formula YPFS seems beneficial for adult AR. This potential benefit need to be further evaluated by more rigorous RCTs.

2 December 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
YHYiwei Hua
Yiwei Hua
XTXi Tan
Xi Tan
JZJingwen Zhang
Jingwen Zhang
NXNingcong Xu
Ningcong Xu
RCRuien Chen
Ruien Chen
YLYunying Li
Yunying Li
Radix Astragali (RA) has been recognized for its therapeutic potential in allergic rhinitis (AR), yet its potential pharmacological mechanisms remain elusive. This study systematically investigated the physicochemical properties and biological activities of RA’s phytochemicals, aiming to elucidate their targets and mechanisms in AR treatment. We identified 775 potential targets of RA’s key phytochemicals and intersected these with 29,544 AR-related disease targets, pinpointing 747 shared therapeutic targets. A protein-protein interaction network analysis categorized these targets into five subclusters, with TNF, NFKB1, IKBKB, NFKBIA, and CHUK emerging as central nodes. Enrichment analysis revealed their roles in inflammatory and immune responses, particularly through the NF-κB, TNF, IL-17, Toll-like receptor, and NOD-like receptor signaling pathways. Molecular docking and dynamics simulations confirmed the strong binding affinity and stability of RA’s phytochemicals to these targets. In vivo, RA intervention effectively reversed the expression of key inflammatory markers in an IL-13-induced nasal mucosa inflammation model. Our findings suggest that RA’s multitargeted approach involves the modulation of critical inflammatory pathways, highlighting its therapeutic potential.



13 September 2025 in Allergy
Verified
Journal Article
Open access
QFQin-Wei Fu
Qin-Wei Fu
PLPeng Liu
Peng Liu
YRYan Ruan
Yan Ruan
XLXin-Rong Li
Xin-Rong Li
LZLan-Zhi Zhang
Lan-Zhi Zhang
QZQinxiu Zhang
Qinxiu Zhang
Allergic rhinitis (AR) is a prevalent chronic condition that significantly impacts patients' quality of life and poses challenges to effective management. Traditional Chinese medicine (TCM) offers a holistic approach, emphasizing syndrome differentiation, individualized care, and natural treatment strategies. To develop comprehensive evidence‐based guidelines for AR management using TCM interventions, incorporating rigorous evidence assessment and expert consensus. The guidelines were developed using the GRADE‐TCM framework, analyzing 351 randomized controlled trials (RCTs) involving 43,276 participants. Supplementary evidence from published textbooks, standardized documents, ancient literature, and TCM medical records was incorporated. Five rounds of expert consensus, involving 80 expert person‐times and over 10,000 valid responses, refined the recommendations. The guidelines provide 32 recommendations covering four primary TCM syndromes (Deficiency‐cold of Lung Qi , Spleen Qi Deficiency and Weakness, Kidney‐ yang Deficiency, and Latent Heat in Lung Meridian) which are mainly involved in AR. These recommendations include both internal interventions (such as herbal and patent medicines) and external therapies (such as acupuncture, moxibustion, and other acupoint‐based treatment). Of these interventions, 10 received strong recommendations, while 22 were classified as weak recommendations. TCM treatments demonstrated significant efficacy in alleviating AR symptoms, reducing recurrence, and improving quality of life. Additionally, TCM can complement conventional AR treatments by reducing the need for pharmacological therapy while maintaining a favorable safety profile. The guidelines integrate classical TCM principles with modern evidence‐based methodologies, offering a structured framework for AR management. They serve as clinical references for practitioners worldwide, supporting a promising approach to AR treatment. Future updates will incorporate emerging evidence and real‐world clinical data to further optimize the role of TCM in AR management.

18 January 2019 in Trials
Verified
Journal Article
Open access
PDF file
QLQiulan Luo
Qiulan Luo
SZShiqing Zhou
Shiqing Zhou
XLXiaoshan Li
Xiaoshan Li
QCQubo Chen
Qubo Chen
WLWenmin Lin
Wenmin Lin
YLYunying Li
Yunying Li
People with allergic rhinitis (AR) often seek help from Chinese medicine due to dissatisfaction with conventional treatments. Lung-spleen qi deficiency syndrome (LSQDS) is the most common type of AR, and the Chinese herbal medicine formula bi min fang (BMF) is commonly prescribed for AR patients with LSQDS. However, direct evidence supporting its efficacy and safety is not available, and its potential mechanism of action remains unclear. This paper presents a double-blind, double-dummy, randomized controlled trial. After a 2-week run-in period, 80 AR patients with LSQDS will be recruited and randomly allocated to the BMF group or the control group in a 1:1 ratio. The patients in the BMF group will receive BMF and the placebo for levocetirizine hydrochloride orally, while the control group participants will receive levocetirizine hydrochloride and the placebo for BMF orally. All participants will receive 4 weeks of treatment and 12 weeks of follow-up. The primary outcome is a change in the Total Nasal Symptom Score (TNSS). Secondary outcomes include changes in scores for the standard version of the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ(S)), and visual analog scale (VAS); changes in serum levels of the cytokines interleukin-4, interferon-γ, transforming growth factor β-1, and interleukin-17; and changes in the gut microbiota composition in the stool. The TNSS, RQLQ(S), and VAS will be recorded at the beginning of, middle of and after the treatment period and at the end of each month in the 3-month follow-up period. Blood and stool samples will be collected at baseline and the end of the treatment. The aforementioned four cytokines will be detected in the serum using enzyme-linked immunosorbent assays, and the stool gut microbiota will be detected using 16S ribosomal ribonucleic acid sequencing. Any side effects of the treatment will be recorded. The results of this trial will provide consolidated evidence of the effect of BMF on AR and the potential mechanism by which BMF acts. This study will be the first to explore the mechanism of action of Chinese herbal medicine on the gut microbiota in AR. Chinese Clinical Trial Registry, ChiCTR-IPR-17010970 . Registered on 23 March 2017.